Sanctuary Advisors LLC Sells 18,488 Shares of GSK plc (NYSE:GSK)

Sanctuary Advisors LLC trimmed its stake in shares of GSK plc (NYSE:GSK) by 6.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 254,072 shares of the pharmaceutical company’s stock after selling 18,488 shares during the quarter. Sanctuary Advisors LLC’s holdings in GSK were worth $8,984,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of GSK. Sunbelt Securities Inc. lifted its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the period. Mesirow Financial Investment Management Inc. lifted its holdings in GSK by 2.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after buying an additional 323 shares during the period. Rehmann Capital Advisory Group lifted its holdings in GSK by 6.3% in the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after buying an additional 332 shares during the period. Investment Partners Asset Management Inc. lifted its holdings in GSK by 2.3% in the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock worth $636,000 after buying an additional 344 shares during the period. Finally, Bond & Devick Financial Network Inc. lifted its holdings in GSK by 5.4% in the 3rd quarter. Bond & Devick Financial Network Inc. now owns 7,830 shares of the pharmaceutical company’s stock worth $320,000 after buying an additional 400 shares during the period. 15.74% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on GSK shares. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Morgan Stanley began coverage on GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Up 1.2 %

GSK stock opened at $36.59 on Wednesday. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a market cap of $75.84 billion, a PE ratio of 23.02, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64. The business has a 50 day moving average of $34.42 and a 200 day moving average of $37.41.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, research analysts forecast that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.30%. The ex-dividend date is Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is 93.08%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.